Related Experiment Video

Updated: Jun 27, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Selectively targeting T- and B-cell lymphomas: a benzothiazole antagonist of alpha4beta1 integrin

Richard D Carpenter1, Mirela Andrei, Olulanu H Aina

  • 1Department of Chemistry, University of California Davis, Davis, California 95616, USA.

Journal of Medicinal Chemistry
|December 17, 2008
PubMed

Insights

Researchers developed a new targeted cancer therapy by modifying a drug that targets Integrin alpha(4)beta(1) on cancer cells. This improved drug maintains potency while offering better properties for potential cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Current chemotherapy lacks cancer cell selectivity, causing side effects.
  • Integrin alpha(4)beta(1) is a cell surface receptor with differential affinity in normal vs. cancerous cells (T- and B-cell lymphomas).

Purpose of the Study:

  • To develop improved diagnostic and chemotherapeutic tools by targeting Integrin alpha(4)beta(1).
  • To overcome pharmacokinetic limitations of previous Integrin alpha(4)beta(1) antagonists.

Main Methods:

  • Utilized heterocyclic and solid-phase chemistry to synthesize novel compounds.
  • Evaluated compound efficacy using cell adhesion assays.
  • Assessed in vivo performance via optical imaging with Cy5.5 conjugates.

Main Results:

  • A novel 2-arylaminobenzothiazole analogue demonstrated improved physicochemical properties, solubility, and kidney:tumor ratio.
  • The analogue maintained high potency, with an IC(50) of 53 pM.
  • Demonstrated selective targeting of Integrin alpha(4)beta(1) in cancer cells.

Conclusions:

  • The 2-arylaminobenzothiazole moiety represents a promising pharmacophore for developing targeted Integrin alpha(4)beta(1) therapies.
  • The new analogue shows potential for improved cancer diagnostics and therapeutics with enhanced drug delivery and reduced toxicity.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...